Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide

Journal of Dermatology

Volumn 34, Issue 4, 2007, Pages 237-242

  Lan, Cheng Che E ^b   Lin, Chi Ling ^b   Wu, Ching Shuang ^b   Chai, Chee Yin ^b   Chen, Wan Tzu ^b   Chen, Gwo Shing ^a,b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Low dose thalidomide; Prurigo nodularis; Taiwanese

Indexed keywords

THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DROWSINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LOW DRUG DOSE; MALE; PAPULAR SKIN DISEASE; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRURIGO; PRURIGO NODULARIS;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PRURIGO; TAIWAN; THALIDOMIDE;

EID: 33847625045     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2007.00260.x     Document Type: Article

References (25)

1. Hardaway WA. Case of multiple tumor of the skin accompanied by intense pruritus. Arch Dermatol 1880; 6: 129-132.
2. Hyde JN. Prurigo nodularis. In: Hyde JN, Montgomery FH (eds). A Practical Treatise on Diseases of the Skin for the Use of Students and Practitioners. Lea and Febiger, Philadelphia, 1909; 174-175.
3. Payne R, Wilkinson JD, McKee PH, Jurecka W, Black MM. Nodular prurigo-a clinicopathological study of 46 patients. Br J Dermatol 1995; 113: 431-439.
4. Doyle JA, Connolly SM, Hunziker N, Winkelmann RK. Prurigo nodularis: a reappraisal of the clinical and histologic features. J Cutan Pathol 1979; 6: 392-403.
5. Sheskin J. Treatment of prurigo nodularis using thalidomide. Hautarzt 1975; 26: 215-217.
6. Faure M, Thivolet J, Gaucherand M. Inhibition of PMN leukocytes chemotaxis by thalidomide. Arch Dermatol Res 1980; 269: 275-280.
7. Sampaio EP, Sarno EN, Galilly R et al. Thalidomide selectively inhibits tumor necrosis factor-α production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
8. Moreira AL, Sampaio EP, Zmuidzinas A et al. Thalidomide exerts its inhibitory action on tumor necrosis factor-α by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-1680.
9. Winkelmann RK, Connolly SM, Doyle JA, Padilha-Goncalves A. Thalidomide treatment of prurigo nodularis. Acta Derm Venereol 1984; 64: 412-417.
10. Van den Broke H. Treatment of prurigo nodularis with thalidomide. Arch Dermatol 1980; 116: 571-572.
11. Mellin GW, Katzenstein M. The saga of thalidomide. Neuropathy and embryopathy, with case reports of congenital abnormalities. N Engl J Med 1962; 267: 1184-1193.
12. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965; 6: 303-306.
13. Radomsky CL, Levine N. Thalidomide. Dermatol Clin 2001; 19: 87-103.
14. Calderon P, Anzilotti M, Phelps R. Thalidomide in dermatology. New indications for an old drug. Int J Dermatol 1997; 36: 881-887.
15. Tseng S, Pak G, Washenik K et al. Rediscovering thalidomide: a review of its mechanism of action, side effects and potential uses. J Am Acad Dermatol 1996; 35: 969-979.
16. Grosshans E, Illy G. Thalidomide therapy for inflammatory dermatosis. Int J Dermatol 1984; 23: 598-602.
17. Stirling DI. Thalidomide and its impact in dermatology. Semin Cutan Med Surg 1998; 17: 231-242.
18. Warren KJ, Nopper AJ, Crosby DL. Thalidomide for recalcitrant discoid lesions in a patients with systemic lupus erythematosus. J Am Acad Dermatol 1998; 39: 293-295.
19. Lee JB, Koblenzer PS. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol 1998; 39: 835-838.
20. Crouch RB, Roley PA, Ng JCH, Baker CS. Thalidomide experience of a major teaching hospital. Australas J Dermatol 2002; 43: 278-284.
21. Wulff CH, Hoyer H, Asboe-Hansen G, Grodthagen H. Development of polyneuropathy during thalidomide therapy. Br J Dermatol 1985; 112: 475-480.
22. Crawford CL. Use of thalidomide in leprosy. Adverse Drug React Toxicol Rev 1994; 13: 188-192.
23. Bastuju-Garin S, Ochonisky S, Bouche P et al. Thalidomide Neuropathy Study Group. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol 2002; 119: 1020-1026.
24. Bonitati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999; 38: 241-251.
25. Qin J-Z, Chaturvedi V, Denning MF et al. Role of NF-κB in the apoptotic-resistant phenotype of keratinocytes. J Biol Chem 2000; 274: 37957-37964.